Abstract P1-06-01: Putting multigene signatures to the test: Prognostic assessment in population-based contemporary clinical breast cancer

Author(s):  
J Staaf ◽  
J Vallon-Christersson ◽  
J Häkkinen ◽  
LH Saal ◽  
C Hegardt ◽  
...  
2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Johan Vallon-Christersson ◽  
Jari Häkkinen ◽  
Cecilia Hegardt ◽  
Lao H. Saal ◽  
Christer Larsson ◽  
...  

2020 ◽  
pp. 27-34 ◽  
Author(s):  
Julie M. Clanahan ◽  
Sanjana Reddy ◽  
Robyn B. Broach ◽  
Anne F. Rositch ◽  
Benjamin O. Anderson ◽  
...  

PURPOSE Globally, breast cancer represents the most common cause of cancer death among women. Early cancer diagnosis is difficult in low- and middle-income countries, most of which are unable to support population-based mammographic screening. Triage on the basis of clinical breast examination (CBE) alone can be difficult to implement. In contrast, piezo-electric palpation (intelligent Breast Exam [iBE]) may improve triage because it is portable, low cost, has a short learning curve, and provides electronic documentation for additional diagnostic workup. We compared iBE and CBE performance in a screening patient cohort from a Western mammography center. METHODS Women presenting for screening or diagnostic workup were enrolled and underwent iBE then CBE, followed by mammography. Mammography was classified as negative (BI-RADS 1 or 2) or positive (BI-RADS 3, 4, or 5). Measures of accuracy and κ score were calculated. RESULTS Between April 2015 and May 2017, 516 women were enrolled. Of these patients, 486 completed iBE, CBE, and mammography. There were 101 positive iBE results, 66 positive CBE results, and 35 positive mammograms. iBE and CBE demonstrated moderate agreement on categorization (κ = 0.53), but minimal agreement with mammography (κ = 0.08). iBE had a specificity of 80.3% and a negative predictive value of 94%. In this cohort, only five of 486 patients had a malignancy; iBE and CBE identified three of these five. The two cancers missed by both modalities were small—a 3-mm retro-areolar and a 1-cm axillary tail. CONCLUSION iBE performs comparably to CBE as a triage tool. Only minimal cancers detected through mammographic screening were missed on iBE. Ultimately, our data suggest that iBE and CBE can synergize as triage tools to significantly reduce the numbers of patients who need additional diagnostic imaging in resource-limited areas.


2021 ◽  
Vol 11 (7) ◽  
pp. 618
Author(s):  
Carlos Martínez-Pérez ◽  
Jess Leung ◽  
Charlene Kay ◽  
James Meehan ◽  
Mark Gray ◽  
...  

Novel biomarkers are needed to continue to improve breast cancer clinical management and outcome. IL6-like cytokines, whose pleiotropic functions include roles in many hallmarks of malignancy, rely on the signal transducer IL6ST (gp130) for all their signalling. To date, 10 separate independent studies based on the analysis of clinical breast cancer samples have identified IL6ST as a predictor. Consistent findings suggest that IL6ST is a positive prognostic factor and is associated with ER status. Interestingly, these studies include 4 multigene signatures (EndoPredict, EER4, IRSN-23 and 42GC) that incorporate IL6ST to predict risk of recurrence or outcome from endocrine or chemotherapy. Here we review the existing evidence on the promising predictive and prognostic value of IL6ST. We also discuss how this potential could be further translated into clinical practice beyond the EndoPredict tool, which is already available in the clinic. The most promising route to further exploit IL6ST’s promising predicting power will likely be through additional hybrid multifactor signatures that allow for more robust stratification of ER+ breast tumours into discrete groups with distinct outcomes, thus enabling greater refinement of the treatment-selection process.


2021 ◽  
pp. 1-5
Author(s):  
Smitha Thomas Kaniyampady ◽  
Srujan Goud Janagam ◽  
Sakshi Thakral

Breast Cancer is the most common type of cancer among women. In addition to the burden of mortality and morbidity, Breast Cancer treatment cost and expenditure comprises a major chunk of the catastrophic health expenditure and financial burden incurred by the population. Delayed hospital presentation and diagnosis augments the hardships faced by individuals, family, community, and the health system at large. The need and urgency to create awareness about the disease and enable early detection via community level population-based screening was identified early in 2014. Through the awareness sessions, the program aims to demystify Breast Cancer and break the stigma associated with it. The intervention adopted a screening methodology that was cost effective and combination of Clinical Breast Examination and Mammography was followed. This paper discusses the learnings and outcomes of the surveillance over the years across geographies spreading awareness.


JAMA Oncology ◽  
2016 ◽  
Vol 2 (7) ◽  
pp. 915 ◽  
Author(s):  
Amy Ming-Fang Yen ◽  
Huei-Shian Tsau ◽  
Jean Ching-Yuan Fann ◽  
Sam Li-Sheng Chen ◽  
Sherry Yueh-Hsia Chiu ◽  
...  

2019 ◽  
Author(s):  
Jonine Figueroa ◽  
Brittny C. Davis Lynn ◽  
Lawrence Edusei ◽  
Nicholas Titiloye ◽  
Ernest Adjei ◽  
...  

2017 ◽  
Vol 48 ◽  
pp. 22-28 ◽  
Author(s):  
Sung-Chao Chu ◽  
Chia-Jung Hsieh ◽  
Tso-Fu Wang ◽  
Mun-Kun Hong ◽  
Tang-Yuan Chu

Sign in / Sign up

Export Citation Format

Share Document